LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol).

Ting Martin Ma,Johannes Czernin,Carol Felix,Rejah Alano,Holly Wilhalme,Luca Valle,Michael L Steinberg,Magnus Dahlbom,Robert E Reiter,Matthew B Rettig,Minsong Cao,Jeremie Calais,Amar U Kishan

BJU international（2023）

引用 2|浏览24

暂无评分

摘要

The addition of Lu-PNT2002 to metastasis-directed therapy alone may potentially further forestall disease progression. The results of this Phase 2 trial will determine, for the first time in a randomized fashion, the added benefit of Lu-PNT2002 to SBRT in patients with oligorecurrent mHSPC.

查看译文

关键词

#ProstateCancer,177Lu-PNT2002,lutetium-177,metastatic hormone-sensitive prostate cancer,oligorecurrent,progression-free survival,prostate cancer,prostate-specific membrane antigen,stereotactic body radiation therapy,trial protocol

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要